Traws Pharma (NASDAQ:TRAW – Get Free Report) released its quarterly earnings data on Monday. The company reported ($0.18) EPS for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.03, Zacks reports.
Traws Pharma Stock Up 3.6%
Shares of Traws Pharma stock opened at $0.26 on Tuesday. The firm’s fifty day simple moving average is $0.42 and its 200-day simple moving average is $1.06. Traws Pharma has a 12 month low of $0.22 and a 12 month high of $3.23.
Wall Street Analysts Forecast Growth
Several equities research analysts recently weighed in on TRAW shares. HC Wainwright restated a “neutral” rating and set a $1.00 target price on shares of Traws Pharma in a research note on Tuesday, August 18th. Weiss Ratings restated a “sell (e+)” rating on shares of Traws Pharma in a research report on Wednesday, August 26th. Four equities research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Reduce” and a consensus price target of $1.00.
Check Out Our Latest Stock Analysis on TRAW
Traws Pharma Company Profile
Traws Pharma is a clinical-stage biopharmaceutical company developing medicines for viral diseases and cancer. Its research includes antiviral candidates aimed at respiratory infections such as COVID-19 and influenza, as well as treatments for cancer. The company’s pipeline includes narazaciclib, an investigational CDK4/6 inhibitor being studied for cancer, and antiviral drug candidates designed to target SARS-CoV-2 and influenza. These products remain in development and are not established as approved treatments.
Read More
- Five stocks we like better than Traws Pharma
- Microsoft’s Outage Barely Moved Its Stock, But a Bigger Risk May Be Building
- MongoDB’s Biggest Advantage May Be GitLab’s Biggest Weakness
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
Receive News & Ratings for Traws Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Traws Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
